803 Efficacy and safety of bevacizumab following prior anti-angiogenic treatment in patients with second-line platinum- based chemotherapy in recurrent ovarian cancer – a subgroup analysis of the AGO-OVAR 2.21 phase III trial
Anca Chelariu-Raiciu, F. Trillsch, P. Harter, Ralf Strobl, J. Sehouli, P. Wimberger, Holger Bronger, Catherine Shannon, C. Lefeuvre, Joern Rau, L. Hanker, Stephan Polterauer, Frederik Marmé, A. El-Balat, Martin R. Stockler, N. Gregorio, Ros Glasspool, Sven Mahner, Alain Lortholary, Jacobus Pfisterer
{"title":"803 Efficacy and safety of bevacizumab following prior anti-angiogenic treatment in patients with second-line platinum- based chemotherapy in recurrent ovarian cancer – a subgroup analysis of the AGO-OVAR 2.21 phase III trial","authors":"Anca Chelariu-Raiciu, F. Trillsch, P. Harter, Ralf Strobl, J. Sehouli, P. Wimberger, Holger Bronger, Catherine Shannon, C. Lefeuvre, Joern Rau, L. Hanker, Stephan Polterauer, Frederik Marmé, A. El-Balat, Martin R. Stockler, N. Gregorio, Ros Glasspool, Sven Mahner, Alain Lortholary, Jacobus Pfisterer","doi":"10.1136/ijgc-2024-esgo.48","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":517822,"journal":{"name":"Oral Sessions","volume":"34 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral Sessions","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ijgc-2024-esgo.48","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
